Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

Brian Godman, Rickard E Malmström, Eduardo Diogene, Andy Gray, Sisira Jayathissa, Angela Timoney, Francisco Acurcio, Ali Alkan, Anna Brzezinska, Anna Bucsics, Stephen M Campbell, Jadwiga Czeczot, Winnie de Bruyn, Irene Eriksson, Faridah Aryani Md Yusof, Alexander E Finlayson, Jurij Fürst, Kristina Garuoliene, Augusto Guerra Júnior, Jolanta Gulbinovič & 20 others Saira Jan, Roberta Joppi, Marija Kalaba, Einar Magnisson, Laura McCullagh, Kaisa Miikkulainen, Gabriela Ofierska-Sujkowska, Hanne Bak Pedersen, Gisbert Selke, Catherine Sermet, Susan Spillane, Azuwana Supian, Ilse Truter, Vera Vlahović-Palčevski, Low Ee Vien, Elif H Vural, Janet Wale, Magdałene Władysiuk, Wenjie Zeng, Lars L Gustafsson

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Medicines have made an appreciable contribution to improving health. However, even high-income countries are struggling to fund new premium-priced medicines. This will grow necessitating the development of new models to optimize their use. The objective is to review case histories among health authorities to improve the utilization and expenditure on new medicines. Subsequently, use these to develop exemplar models and outline their implications. A number of issues and challenges were identified from the case histories. These included the low number of new medicines seen as innovative alongside increasing requested prices for their reimbursement, especially for oncology, orphan diseases, diabetes and HCV. Proposed models center on the three pillars of pre-, peri- and post-launch including critical drug evaluation, as well as multi-criteria models for valuing medicines for orphan diseases alongside potentially capping pharmaceutical expenditure. In conclusion, the proposed models involving all key stakeholder groups are critical for the sustainability of healthcare systems or enhancing universal access. The models should help stimulate debate as well as restore trust between key stakeholder groups.
LanguageEnglish
Pages77-94
Number of pages18
JournalExpert Review of Clinical Pharmacology
Volume8
Issue number1
DOIs
Publication statusPublished - 1 Jan 2015

Fingerprint

Health Expenditures
Rare Diseases
Delivery of Health Care
Drug Evaluation
Health
Financial Management
Pharmaceutical Preparations

Keywords

  • clinical pharmacology
  • critical drug evaluation
  • dabigatran
  • differential pricing
  • ivacaftor
  • managed entry agreements
  • new models
  • rational use of medicines
  • sofosbuvir
  • trastuzumab emtansine
  • adalimumab
  • etanercept
  • cancer therapy
  • cerebrovascular accident
  • cost effectiveness analysis
  • diabetes mellitus
  • drug industry
  • drug screening
  • drug utilization
  • embolism
  • France
  • health care system
  • health care utilization
  • heart atrium fibrillation
  • human
  • medical decision making
  • medicine
  • oncology
  • phase 3 clinical trial (topic)
  • reimbursement

Cite this

Godman, Brian ; Malmström, Rickard E ; Diogene, Eduardo ; Gray, Andy ; Jayathissa, Sisira ; Timoney, Angela ; Acurcio, Francisco ; Alkan, Ali ; Brzezinska, Anna ; Bucsics, Anna ; Campbell, Stephen M ; Czeczot, Jadwiga ; de Bruyn, Winnie ; Eriksson, Irene ; Yusof, Faridah Aryani Md ; Finlayson, Alexander E ; Fürst, Jurij ; Garuoliene, Kristina ; Guerra Júnior, Augusto ; Gulbinovič, Jolanta ; Jan, Saira ; Joppi, Roberta ; Kalaba, Marija ; Magnisson, Einar ; McCullagh, Laura ; Miikkulainen, Kaisa ; Ofierska-Sujkowska, Gabriela ; Pedersen, Hanne Bak ; Selke, Gisbert ; Sermet, Catherine ; Spillane, Susan ; Supian, Azuwana ; Truter, Ilse ; Vlahović-Palčevski, Vera ; Vien, Low Ee ; Vural, Elif H ; Wale, Janet ; Władysiuk, Magdałene ; Zeng, Wenjie ; Gustafsson, Lars L . / Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?. In: Expert Review of Clinical Pharmacology. 2015 ; Vol. 8, No. 1. pp. 77-94.
@article{78b33e5e33c5402394803d96ff83a877,
title = "Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?",
abstract = "Medicines have made an appreciable contribution to improving health. However, even high-income countries are struggling to fund new premium-priced medicines. This will grow necessitating the development of new models to optimize their use. The objective is to review case histories among health authorities to improve the utilization and expenditure on new medicines. Subsequently, use these to develop exemplar models and outline their implications. A number of issues and challenges were identified from the case histories. These included the low number of new medicines seen as innovative alongside increasing requested prices for their reimbursement, especially for oncology, orphan diseases, diabetes and HCV. Proposed models center on the three pillars of pre-, peri- and post-launch including critical drug evaluation, as well as multi-criteria models for valuing medicines for orphan diseases alongside potentially capping pharmaceutical expenditure. In conclusion, the proposed models involving all key stakeholder groups are critical for the sustainability of healthcare systems or enhancing universal access. The models should help stimulate debate as well as restore trust between key stakeholder groups.",
keywords = "clinical pharmacology, critical drug evaluation, dabigatran, differential pricing, ivacaftor, managed entry agreements, new models, rational use of medicines, sofosbuvir, trastuzumab emtansine, adalimumab, etanercept, cancer therapy, cerebrovascular accident, cost effectiveness analysis, diabetes mellitus, drug industry, drug screening, drug utilization, embolism, France, health care system, health care utilization, heart atrium fibrillation, human, medical decision making, medicine, oncology, phase 3 clinical trial (topic), reimbursement",
author = "Brian Godman and Malmstr{\"o}m, {Rickard E} and Eduardo Diogene and Andy Gray and Sisira Jayathissa and Angela Timoney and Francisco Acurcio and Ali Alkan and Anna Brzezinska and Anna Bucsics and Campbell, {Stephen M} and Jadwiga Czeczot and {de Bruyn}, Winnie and Irene Eriksson and Yusof, {Faridah Aryani Md} and Finlayson, {Alexander E} and Jurij F{\"u}rst and Kristina Garuoliene and {Guerra J{\'u}nior}, Augusto and Jolanta Gulbinovič and Saira Jan and Roberta Joppi and Marija Kalaba and Einar Magnisson and Laura McCullagh and Kaisa Miikkulainen and Gabriela Ofierska-Sujkowska and Pedersen, {Hanne Bak} and Gisbert Selke and Catherine Sermet and Susan Spillane and Azuwana Supian and Ilse Truter and Vera Vlahović-Palčevski and Vien, {Low Ee} and Vural, {Elif H} and Janet Wale and Magdałene Władysiuk and Wenjie Zeng and Gustafsson, {Lars L}",
year = "2015",
month = "1",
day = "1",
doi = "10.1586/17512433.2015.990380",
language = "English",
volume = "8",
pages = "77--94",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
number = "1",

}

Godman, B, Malmström, RE, Diogene, E, Gray, A, Jayathissa, S, Timoney, A, Acurcio, F, Alkan, A, Brzezinska, A, Bucsics, A, Campbell, SM, Czeczot, J, de Bruyn, W, Eriksson, I, Yusof, FAM, Finlayson, AE, Fürst, J, Garuoliene, K, Guerra Júnior, A, Gulbinovič, J, Jan, S, Joppi, R, Kalaba, M, Magnisson, E, McCullagh, L, Miikkulainen, K, Ofierska-Sujkowska, G, Pedersen, HB, Selke, G, Sermet, C, Spillane, S, Supian, A, Truter, I, Vlahović-Palčevski, V, Vien, LE, Vural, EH, Wale, J, Władysiuk, M, Zeng, W & Gustafsson, LL 2015, 'Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?' Expert Review of Clinical Pharmacology, vol. 8, no. 1, pp. 77-94. https://doi.org/10.1586/17512433.2015.990380

Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? / Godman, Brian; Malmström, Rickard E; Diogene, Eduardo; Gray, Andy; Jayathissa, Sisira; Timoney, Angela; Acurcio, Francisco; Alkan, Ali; Brzezinska, Anna; Bucsics, Anna; Campbell, Stephen M; Czeczot, Jadwiga; de Bruyn, Winnie; Eriksson, Irene; Yusof, Faridah Aryani Md; Finlayson, Alexander E; Fürst, Jurij; Garuoliene, Kristina; Guerra Júnior, Augusto; Gulbinovič, Jolanta; Jan, Saira; Joppi, Roberta; Kalaba, Marija; Magnisson, Einar; McCullagh, Laura; Miikkulainen, Kaisa; Ofierska-Sujkowska, Gabriela; Pedersen, Hanne Bak; Selke, Gisbert; Sermet, Catherine; Spillane, Susan; Supian, Azuwana; Truter, Ilse; Vlahović-Palčevski, Vera; Vien, Low Ee; Vural, Elif H; Wale, Janet; Władysiuk, Magdałene; Zeng, Wenjie; Gustafsson, Lars L .

In: Expert Review of Clinical Pharmacology, Vol. 8, No. 1, 01.01.2015, p. 77-94.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

AU - Godman, Brian

AU - Malmström, Rickard E

AU - Diogene, Eduardo

AU - Gray, Andy

AU - Jayathissa, Sisira

AU - Timoney, Angela

AU - Acurcio, Francisco

AU - Alkan, Ali

AU - Brzezinska, Anna

AU - Bucsics, Anna

AU - Campbell, Stephen M

AU - Czeczot, Jadwiga

AU - de Bruyn, Winnie

AU - Eriksson, Irene

AU - Yusof, Faridah Aryani Md

AU - Finlayson, Alexander E

AU - Fürst, Jurij

AU - Garuoliene, Kristina

AU - Guerra Júnior, Augusto

AU - Gulbinovič, Jolanta

AU - Jan, Saira

AU - Joppi, Roberta

AU - Kalaba, Marija

AU - Magnisson, Einar

AU - McCullagh, Laura

AU - Miikkulainen, Kaisa

AU - Ofierska-Sujkowska, Gabriela

AU - Pedersen, Hanne Bak

AU - Selke, Gisbert

AU - Sermet, Catherine

AU - Spillane, Susan

AU - Supian, Azuwana

AU - Truter, Ilse

AU - Vlahović-Palčevski, Vera

AU - Vien, Low Ee

AU - Vural, Elif H

AU - Wale, Janet

AU - Władysiuk, Magdałene

AU - Zeng, Wenjie

AU - Gustafsson, Lars L

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Medicines have made an appreciable contribution to improving health. However, even high-income countries are struggling to fund new premium-priced medicines. This will grow necessitating the development of new models to optimize their use. The objective is to review case histories among health authorities to improve the utilization and expenditure on new medicines. Subsequently, use these to develop exemplar models and outline their implications. A number of issues and challenges were identified from the case histories. These included the low number of new medicines seen as innovative alongside increasing requested prices for their reimbursement, especially for oncology, orphan diseases, diabetes and HCV. Proposed models center on the three pillars of pre-, peri- and post-launch including critical drug evaluation, as well as multi-criteria models for valuing medicines for orphan diseases alongside potentially capping pharmaceutical expenditure. In conclusion, the proposed models involving all key stakeholder groups are critical for the sustainability of healthcare systems or enhancing universal access. The models should help stimulate debate as well as restore trust between key stakeholder groups.

AB - Medicines have made an appreciable contribution to improving health. However, even high-income countries are struggling to fund new premium-priced medicines. This will grow necessitating the development of new models to optimize their use. The objective is to review case histories among health authorities to improve the utilization and expenditure on new medicines. Subsequently, use these to develop exemplar models and outline their implications. A number of issues and challenges were identified from the case histories. These included the low number of new medicines seen as innovative alongside increasing requested prices for their reimbursement, especially for oncology, orphan diseases, diabetes and HCV. Proposed models center on the three pillars of pre-, peri- and post-launch including critical drug evaluation, as well as multi-criteria models for valuing medicines for orphan diseases alongside potentially capping pharmaceutical expenditure. In conclusion, the proposed models involving all key stakeholder groups are critical for the sustainability of healthcare systems or enhancing universal access. The models should help stimulate debate as well as restore trust between key stakeholder groups.

KW - clinical pharmacology

KW - critical drug evaluation

KW - dabigatran

KW - differential pricing

KW - ivacaftor

KW - managed entry agreements

KW - new models

KW - rational use of medicines

KW - sofosbuvir

KW - trastuzumab emtansine

KW - adalimumab

KW - etanercept

KW - cancer therapy

KW - cerebrovascular accident

KW - cost effectiveness analysis

KW - diabetes mellitus

KW - drug industry

KW - drug screening

KW - drug utilization

KW - embolism

KW - France

KW - health care system

KW - health care utilization

KW - heart atrium fibrillation

KW - human

KW - medical decision making

KW - medicine

KW - oncology

KW - phase 3 clinical trial (topic)

KW - reimbursement

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-84916931880&partnerID=40&md5=3df3f7d6ddfddd8f4dada588959aedc5

U2 - 10.1586/17512433.2015.990380

DO - 10.1586/17512433.2015.990380

M3 - Article

VL - 8

SP - 77

EP - 94

JO - Expert Review of Clinical Pharmacology

T2 - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 1

ER -